The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

II.b

ARDS - Acute lung injury

Publications

Gibelin A, Parrot A, Maitre B, Brun-Buisson C, Mekontso Dessap A, Fartoukh M, de Prost N

Acute respiratory distress syndrome mimickers lacking common risk factors of the Berlin definition.

Intensive care medicine. 2016;42(2):164-72

Ren S, Li Y, Li W, Zhao Z, Jin C, Zhang D

Fatal asymmetric interstitial lung disease after erlotinib for lung cancer.

Respiration; international review of thoracic diseases. 2012;84(5):431-5

ter Heine R, van den Bosch RT, Schaefer-Prokop CM, Lankheet NA, Beijnen JH, Staaks GH, van der Westerlaken MM, Malingré MM, van den Brand JJ

Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.

Lung cancer (Amsterdam, Netherlands). 2012;75(3):391-7

Del Castillo Y, Espinosa P, Bodí F, Alcega R, Muñoz E, Rabassó C, Castander D

Interstitial lung disease associated to erlotinib treatment: a case report.

Cases journal. 2010;3:59

Um SJ, Lee SK, Yang DK, Son C, Roh MS, Kim KN, Lee KN, Choi PJ

Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.

The clinical respiratory journal. 2009;3(3):181-4

Chou CL, Ko HW, Wang CW, Yu CT, Kuo HP, Huang CD

Erlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinoma.

Chang Gung medical journal. 2010;33(1):100-5

Liu V, White DA, Zakowski MF, Travis W, Kris MG, Ginsberg MS, Miller VA, Azzoli CG

Pulmonary toxicity associated with erlotinib.

Chest. 2007;132(3):1042-4

Vahid B, Esmaili A

Erlotinib-associated acute pneumonitis: report of two cases.

Canadian respiratory journal. 2007;14(3):167-70